Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the vaccine protects vulnerable infants

RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”

The pregnancy vaccine works by stimulating the mother’s body’s defences to produce defence proteins, which are then transferred to the foetus through the placenta. This mother-derived protection provides newborns with immediate protection from the point of delivery, precisely when they are highly susceptible to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.

• Nearly 85 per cent protection when vaccinated four weeks before birth
• Antibodies from the mother transferred through the placenta safeguard newborns from birth
• Protection achievable with two-week gap before premature birth
• Vaccination during third trimester still offers meaningful protection for infants

Persuasive evidence from the latest research

The efficacy of the pregnancy RSV vaccine has been confirmed through a comprehensive study undertaken in England, examining data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that six-month timeframe, providing strong and reliable data of the vaccine’s actual performance. The study’s results have been supported by the UK Health Security Agency as showing strong protection for newborns during their earliest and most vulnerable period. The breadth of this investigation provides healthcare professionals and parents-to-be with assurance in the vaccine’s proven efficacy across different groups and contexts.

The results reveal a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV during the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This clear distinction highlights the vaccine’s vital importance in preventing serious illness in newborns. The decrease in hospital admissions above 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme introduced in the UK in 2024.

Study design and parameters

The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospitalisations. The large sample size and thorough nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than isolated cases or limited subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology measured real-world outcomes rather than experimental conditions, providing real-world data of how the vaccine works when delivered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.

Learning about RSV and its threats

Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.

The infection produces deep inflammation in the lungs and airways, making it extremely challenging for infected babies to breathe and feed properly. Parents frequently observe their babies struggling visibly, their chests rising whilst they attempt to draw sufficient oxygen into their weakened respiratory system. Whilst the majority of babies improve through clinical support, a limited though important proportion perish from RSV complications each year, making vaccination as prevention a vital health service imperative for defending the youngest and most vulnerable members of society.

• RSV causes lung inflammation, resulting in severe breathing difficulties in babies
• Nearly 50% of infants acquire the virus during their first few months alive
• Symptoms vary between mild colds to serious chest infections that threaten life needing hospital treatment
• More than 20,000 UK infants need serious hospital treatment for RSV each year
• A small number of babies succumb to RSV related complications annually in the UK

Uptake rates and professional guidance

Since the RSV vaccine programme launched in 2024, health officials have stressed the importance of pregnant women receiving their jab at the ideal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that timing matters greatly for ensuring newborns benefit from the maximum immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers nearly 85% protection, experts advise women to get their vaccine as early as possible from 28 weeks of pregnancy forward to increase the antibodies transferred to their babies through the placenta.

The messaging from public health bodies stays clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured expectant mothers that protection remains still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This flexible approach recognises the practical demands of pregnancy whilst ensuring strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.

Regional disparities in vaccine uptake

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have attained higher vaccination coverage among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These geographical variations demonstrate differences across medical facilities, communication strategies, and local engagement efforts, though the overall statistics demonstrates consistently strong protection regardless of geographical location.

• NHS trusts launching multiple messaging strategies to engage with pregnant women
• Inconsistencies across regions in immunisation take-up across England necessitate strategic intervention
• Community health services adapting programmes to align with specific population needs

Real-world impact and parent viewpoints

The vaccine’s impressive effectiveness translates into concrete gains for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the launch of this safeguarding intervention, the 80% drop in admissions represents thousands of infants protected against critical disease. Parents no more face the upsetting situation of seeing their babies gasping for air or labour to feed, symptoms that define critical RSV illness. The vaccine has fundamentally shifted the landscape of neonatal lung health, offering expectant mothers a preventative option to safeguard their most vulnerable children during those crucial first weeks.

For families like that of Malachi, whose acute RSV infection resulted in devastating brain damage, the vaccine’s availability carries significant emotional significance. His mother’s support of the jab underscores the life-altering consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such serious complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to expectant mothers during their late pregnancy, changing what was once an unavoidable seasonal threat into a controllable health concern.